Lorenz Thurner

Loncastuximab tesirine in heavily pretreated patients with large B-cell lymphoma: a German Lymphoma Alliance analysis

Evgenii Shumilov, Lina Kolloch, Philipp Faustmann, Débora-Michèle Grote Urtubey et autres

For patients with large B-cell lymphoma progressing after multiple lines of therapy few treatment options remain, including the new CD19-directed antibody-drug conjugate loncastuximab tesirine (lonca). To further elucidate its efficacy and safety, we conducted a real-world analysis including data from 31 German …

de, us (code pays fourni par la source)

Neutralizing autoantibodies against IL-1Ra in severe bacterial community-acquired pneumonia

Sophie Trouillet‐Assant, Kylian Trepat, Natalie Fadle, Priscille Franc et autres

fr, de, nl (code pays fourni par la source)

AI for prognostic assessment of diffuse large B‐cell lymphoma using H&E whole‐slide images

Jonas Lippl, Sarah Reinke, Stefan Schrod, Lukas Wolfseher et autres

Abstract Prediction of the outcome of large B‐cell lymphomas/high‐grade B‐cell lymphomas (DLBCLs/HGBCLs) is based on clinical parameters and molecular testing, for example, for rearrangements of MYC (MYC‐R) and MYC‐R in combination with BCL2 and BCL6 translocations (double/triple hit). However, the group of …

de, ca (code pays fourni par la source)

Proinflammatory autoantibodies enhancing tumor necrosis factor and RANKL signaling in axial spondyloarthritis associate with hyperphosphorylated progranulin and osteoprotegerin

Zanir Abdi, Natalie Fadle, Evi Regitz, Igor Age Kos et autres

de (code pays fourni par la source)

Autoantibodies to IL-1Ra and PGRN in severe COVID-19 are associated with inflammation-induced hyperphosphorylated antigen isoforms

Lorenz Thurner, Natalie Fadle, Bernhard Thurner, Igor Age Kos et autres

SARS-CoV-2 infection affects multiple immune mechanisms and leads to severe COVID-19 and death, in part related to infection-induced or pre-existing autoantibodies. Here, we describe severe COVID-19 to associate with autoantibodies against interleukin-1 receptor antagonist (IL-1Ra) and progranulin (PGRN), endogenous antagonists of IL-1 …

de, lu, us, pl (code pays fourni par la source)

R-CHOP in B cell non-Hodgkin lymphoma: balancing anti-tumor efficacy and NK-cell functionality

Johanna Jansky, Hannah Breitung, Sylvia Zöphel, Laetitia Döngi et autres

Abstract Combining the anti-CD20 antibody rituximab with the chemotherapeutic drugs vincristine, doxorubicin, and cyclophosphamide plus the corticosteroid prednisone (R-CHOP) has been the standard first line-line therapy for many non-Hodgkin lymphomas including diffuse large B-cell lymphoma (DLBCL) for more than 20 years. Natural …

de (code pays fourni par la source)

Impact of Perforin 1 A91V germ line background in patients with aggressive B-NHL treated with R-CHOP

Onur Cetin, Igor Age Kos, Evi Regitz, Moritz Bewarder et autres

Rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) is a critical mechanism in the treatment of B-cell malignancies.The effectiveness of ADCC depends on multiple factors, including rituximab binding, granule release, perforin/granzyme concentration, and the expression of deathinducing ligands.This study aimed to determine whether genetic variants …

de, fr (code pays fourni par la source)

Impact of PRF 1 A91V germline carrier status in patients with aggressive b-NHL treated with rituximab

Onur Cetin, Igor Age Kos, Evi Regitz, Moritz Bewarder et autres

Abstract INTRODUCTION Rituximab mediated antibody-dependent cellular cytotoxicity (ADCC) is an essential component of therapy in B-cell malignancies. The efficiency of cellular cytotoxicity depends on many factors including rituximab binding, lytic granule release and perforin/granzyme concentration, or expression of death-inducing ligands. Here we …

de, us, lu (code pays fourni par la source)

Impact of extranodal involvement in stage I aggressive B-cell lymphoma in the rituximab era: An individual patient data meta-analysis of two Phase III dshnhl/GLA trials

Konstantinos Christofyllakis, Vadim Lesan, Moritz Bewarder, Bettina Altmann et autres

Abstract Background: The prognostic impact of extranodal stage I large B-cell lymphoma (LBCL) in the rituximab era remains unclear, and the role of consolidative radiotherapy (RT) for all patients without primary refractory disease is debated. We performed an individual patient data meta-analysis …

de (code pays fourni par la source)

Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma

Thomas Oellerich, Rebecca Wurm‐Kuczera, Shashwat Sahay, Meng Wang et autres

Abstract Background Relapsed and refractory large B-cell lymphomas (r/r LBCL) remain a therapeutic challenge, particularly after CAR-T cell therapy or bispecific antibodies, where prognosis is dismal with no standard treatment. VIPOR(P) is a biologically guided, multi-targeted regimen combining venetoclax (V), ibrutinib (i), …

de, us, at, sk (code pays fourni par la source)

Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT

Lin Li, Yishan Ye, Jacques‐Emmanuel Galimard, Depei Wu et autres

Abstract Background Acute myeloid leukemia (AML) with NUP98 rearrangements on chromosome 11p15 is a high-risk subtype with poor prognosis. Due to its rarity, the impact of allogeneic hematopoietic cell transplantation (allo-HCT) in these patients remains unclear. Patients and Methods Data from 147 …

cn, fr, fi, cz, it, jp, gb, be, de, lb, il, pl (code pays fourni par la source)

Secondary hemophagocytic lymphohistiocytosis associated with adjuvant pembrolizumab therapy in a young patient with triple-negative breast cancer: a case report with literature review

Gregor Leonhard Olmes, Meletios P. Nigdelis, Bashar Haj Hamoud, E.-F. Solomayer et autres

PURPOSE: Secondary hemophagocytic lymphohistiocytosis (HLH) associated with pembrolizumab is a rare immune-related adverse event (irAE). It features a potential life-threatening status including fever and a hyperinflammatory reaction caused by natural killer cells, CD8 + cytotoxic T cells, and antigen-presenting cells leading to …

de (code pays fourni par la source)